[{"address1": "Wallstra\u00dfe 16", "city": "Berlin", "zip": "10179", "country": "Germany", "phone": "49 89 2153 9035", "website": "https://atai.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.", "fullTimeEmployees": 54, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christian  Angermayer", "age": 46, "title": "Founder & Chairman of the Supervisory Board", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 73104, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Srinivas G. Rao M.D., Ph.D.", "age": 55, "title": "Co-Founder & CEO", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 834460, "exercisedValue": 0, "unexercisedValue": 39375}, {"maxAge": 1, "name": "Ms. Anne  Johnson", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 574815, "exercisedValue": 0, "unexercisedValue": 32812}, {"maxAge": 1, "name": "Dr. Gerd G. Kochendoerfer Ph.D.", "age": 56, "title": "Chief Operating Officer", "yearBorn": 1968, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Glenn  Short Ph.D.", "age": 54, "title": "Chief Scientific Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Barrett J.D.", "age": 43, "title": "General Counsel & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevin  Craig M.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.32, "open": 2.26, "dayLow": 2.18, "dayHigh": 2.3299, "regularMarketPreviousClose": 2.32, "regularMarketOpen": 2.26, "regularMarketDayLow": 2.18, "regularMarketDayHigh": 2.3299, "payoutRatio": 0.0, "beta": 1.225, "forwardPE": -3.3970587, "volume": 1661854, "regularMarketVolume": 1661854, "averageVolume": 1876823, "averageVolume10days": 3121690, "averageDailyVolume10Day": 3121690, "bid": 2.28, "ask": 2.35, "bidSize": 31, "askSize": 55, "marketCap": 462780768, "fiftyTwoWeekLow": 1.03, "fiftyTwoWeekHigh": 2.565, "priceToSalesTrailing12Months": 248.4062, "fiftyDayAverage": 1.5495, "twoHundredDayAverage": 1.46975, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 393764864, "profitMargins": 0.0, "floatShares": 102558832, "sharesOutstanding": 200338000, "sharesShort": 12789515, "sharesShortPriorMonth": 12136294, "sharesShortPreviousMonthDate": 1744675200, "dateShortInterest": 1747267200, "sharesPercentSharesOut": 0.0638, "heldPercentInsiders": 0.08259, "heldPercentInstitutions": 0.32687, "shortRatio": 9.5, "shortPercentOfFloat": 0.0834, "impliedSharesOutstanding": 200338000, "bookValue": 0.761, "priceToBook": 3.0354795, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -148987008, "trailingEps": -0.91, "forwardEps": -0.68, "enterpriseToRevenue": 211.361, "enterpriseToEbitda": -4.091, "52WeekChange": 0.43478262, "SandP52WeekChange": 0.1189177, "quoteType": "EQUITY", "currentPrice": 2.31, "targetHighPrice": 11.0, "targetLowPrice": 5.0, "targetMeanPrice": 8.0, "targetMedianPrice": 8.0, "recommendationMean": 1.28571, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 98204000, "totalCashPerShare": 0.49, "ebitda": -96251000, "totalDebt": 28968000, "quickRatio": 3.498, "currentRatio": 4.069, "totalRevenue": 1863000, "debtToEquity": 19.024, "revenuePerShare": 0.011, "returnOnAssets": -0.26042, "returnOnEquity": -0.79427004, "grossProfits": 2255000, "freeCashflow": -47041248, "operatingCashflow": -77705000, "grossMargins": 1.21041, "ebitdaMargins": 0.0, "operatingMargins": -12.392281, "financialCurrency": "USD", "symbol": "ATAI", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1748649318, "regularMarketTime": 1748635202, "exchange": "NGM", "messageBoardId": "finmb_710359021", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "longName": "Atai Life Sciences N.V.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1624023000000, "postMarketChangePercent": -0.4329, "postMarketPrice": 2.3, "postMarketChange": -0.00999999, "regularMarketChange": -0.00999999, "regularMarketDayRange": "2.18 - 2.3299", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1876823, "fiftyTwoWeekLowChange": 1.28, "fiftyTwoWeekLowChangePercent": 1.2427185, "fiftyTwoWeekRange": "1.03 - 2.565", "fiftyTwoWeekHighChange": -0.2550001, "fiftyTwoWeekHighChangePercent": -0.09941525, "fiftyTwoWeekChangePercent": 43.478264, "earningsTimestamp": 1747220400, "shortName": "ATAI Life Sciences N.V.", "earningsTimestampStart": 1755084600, "earningsTimestampEnd": 1755084600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.91, "epsForward": -0.68, "epsCurrentYear": -0.5, "priceEpsCurrentYear": -4.62, "fiftyDayAverageChange": 0.76049995, "fiftyDayAverageChangePercent": 0.49080345, "twoHundredDayAverageChange": 0.8402499, "twoHundredDayAverageChangePercent": 0.5716958, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-18", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "regularMarketChangePercent": -0.431034, "regularMarketPrice": 2.31, "displayName": "Atai Life Sciences", "trailingPegRatio": null, "__fetch_time": "2025-05-31"}]